John W Rose Selected Research

Daclizumab (Zenapax)

10/2017	Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
10/2017	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
1/2014	Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
4/2010	Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
9/2009	Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
12/2004	Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John W Rose Research Topics

Disease

21	Multiple Sclerosis 10/2017 - 04/2002
6	Demyelinating Diseases (Demyelinating Disease) 11/2013 - 04/2002
5	Relapsing-Remitting Multiple Sclerosis 10/2017 - 09/2009
3	Autoimmune Diseases (Autoimmune Disease) 05/2009 - 12/2006
2	Inflammation (Inflammations) 11/2013 - 06/2004
2	Disease Progression 05/2013 - 02/2013
2	Chronic Progressive Multiple Sclerosis 12/2009 - 12/2004
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2021
1	Infections 10/2017
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2013
1	Urinary Tract Infections (Urinary Tract Infection) 01/2013
1	Atrophy 11/2012
1	Gliosis 06/2006
1	Optic Neuritis (Retrobulbar Neuritis) 06/2006

Drug/Important Bio-Agent (IBA)

6	Daclizumab (Zenapax)FDA Link 10/2017 - 12/2004
4	Monoclonal AntibodiesIBA 04/2010 - 12/2004
3	EnzymesIBA 10/2017 - 06/2004
3	Biomarkers (Surrogate Marker)IBA 05/2013 - 05/2011
2	Interferon beta-1a FDA Link 10/2017 - 04/2002
2	Interferon-betaIBA 02/2013 - 04/2010
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2010 - 04/2004
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 06/2006 - 06/2004
1	Immunoglobulins (Immunoglobulin)IBA 10/2021
1	Antinuclear AntibodiesIBA 10/2021
1	Retinaldehyde (Retinal)IBA 06/2015
1	Interleukin-2 (IL2)IBA 01/2014
1	ResveratrolIBA 11/2013
1	Vitamin D FDA LinkGeneric 05/2013
1	Neutralizing AntibodiesIBA 02/2013
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2013
1	CytokinesIBA 11/2011
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2010
1	GadoliniumIBA 04/2010
1	Immunoglobulin M (IgM)IBA 12/2009
1	AntibodiesIBA 12/2009
1	2',3'-Cyclic-Nucleotide Phosphodiesterases (2',3' Cyclic Nucleotide Phosphodiesterase)IBA 06/2006
1	3-nitrotyrosineIBA 06/2006
1	Caspase 3 (Caspase-3)IBA 05/2006
1	Protein Isoforms (Isoforms)IBA 05/2006
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 05/2006
1	AntioxidantsIBA 01/2006
1	Interleukin-2 Receptor alpha SubunitIBA 12/2004
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2004
1	Glutamic Acid (Glutamate)FDA Link 04/2004
1	Myelin Basic ProteinIBA 04/2004
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2002

Therapy/Procedure

7	Therapeutics 02/2013 - 01/2006
1	Injections 01/2013
1	Hematopoietic Stem Cell Transplantation 12/2006
1	Lasers (Laser) 06/2004
1	Intramuscular Injections 04/2002